cyrilzakka/clinical-trials huggingface dataset:
Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Prednisone may help to relieve symptoms in patients with recurrent and/or metastatic kidney cancer.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy consisting of vinorelbine and estramustine with or without prednisone in treating patients who have recurrent and/or metastatic kidney cancer.

OBJECTIVES: I. Estimate the response rate of vinorelbine and estramustine in patients with metastatic and/or recurrent renal cell carcinoma. II. Obtain pilot data exploring the value of anti-inflammatory treatment in the management of severe systemic symptoms and improvement of treatment tolerance in this patient population.

OUTLINE: Patients are stratified according to number of risk factors (0,1 versus 2 versus 3). Patients receive vinorelbine IV on days 1, 8, 15, 22, 28, and 35. Patients also receive estramustine orally twice per day on days 1-7 and an increased dose on days 8-42. A tapered dose of oral prednisone is given to patients with an elevated erythrocyte sedimentation rate. A course of treatment consists of 6 weeks of treatment followed by 2 weeks of rest. Patients with stable disease may receive up to 4 courses of treatment. Patients who achieve a partial response may undergo surgical resection followed by up to 2 additional courses of treatment or an interleukin-2 treatment regimen. Patients with a complete response receive 1 additional course of treatment. Patients are followed until death.

PROJECTED ACCRUAL: A maximum of 35 patients will be accrued for this study.

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven metastatic and/or recurrent renal cell carcinoma Bidimensionally measurable disease required (outside any prior radiation fields) No untreated brain metastases

PATIENT CHARACTERISTICS: Age: Not specified Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not pregnant or nursing Fertile patients must use effective contraception No other serious illness No serious active infection requiring therapy HIV negative

PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy Chemotherapy: No prior vinca alkaloid No other concurrent chemotherapy Endocrine therapy: No concurrent hormone therapy No concurrent corticosteroids (topical or inhaled corticosteroids allowed) Radiotherapy: At least 4 weeks since prior radiotherapy Less than 25% of bone marrow irradiated No concurrent radiotherapy Surgery: At least 3 weeks since prior surgery Other: No other concurrent investigational drugs
Using Xenograft Combined With Barrier Membrane to Improve the Formation of Deep Periodontal Pockets

To evaluate the clinical effect of site preservation after third molars extraction by using tooth extraction of third molars with site preservation using bio-oss and bio-guide in preventing the formation of deep periodontal pockets in the distal of second molars.

The mandibular third molar is the last tooth to erupt in the dentition, and due to the insufficient eruption position, it can lead to different degrees of impact. During the eruption of impacted tooth, the crown may be partially or completely covered by the gingival flap. A deep blind pocket is formed between the gingival flap and the tooth crown, and food and bacteria are easily impinged in the blind pocket. Under the influence of oral environment and dental plaque, the presence of blind pockets can lead to the loss of periodontal attachment and the absorption of alveolar bone, thus affecting the distal periodontal status of adjacent molars.

Organic bone xenograft material composed of absorbable organic bovine hydroxyapatite is one of the commonly used transplantation materials for repairing bone defects. The application effect of allogeneic bone materials in periodontal therapy has been recognized by many experts and scholars. Guided bone regeneration (GBR), as a conventional periodontal bone graft, has achieved good results in periodontal tissue regeneration. Aljuboori et al. found that when the third molar was removed and GBR was performed at the same time, the depth of distal periodontal pocket probing of the adjacent second molar was significantly reduced in the re-examination 6 months after surgery.

Hence, this study intends to use xenograft combined with barrier membrane to improve the formation of distal periodontal pocket of the second molars after third molars extraction.

Eligibility Criteria:
Inclusion Criteria:

* 26-45 years old
* Completely or partially impacted mandibular third molar
* No evidence of acute inflammation
* In good physical status and oral health
* Regular attendance at control visits

Exclusion Criteria:

* pregnancy or lactation
* Aggregate systemic pathologies such as diabetes, thyroid disorders, bone metabolism diseases, among others
* Patients taking calcium, bisphosphonates, glucocorticoids, or other drugs that can interfere with bone metabolism
* Patients with uncontrolled periodontal conditions, endodontic conditions and other oral disorders
* Heavy smoke (10 cigarettes/day or more)
* The second molar has no contact with the third molar, or the third molar crown has alveolar bone
BEACON Care ® System Assisting Ventilation in Pressure Support Ventilation (PSV) Patient

The aim of this study is to evaluate the ventilator settings advice given by the BEACON care system in fitting with best level of support in patient under mechanical ventilation in Pressure Support mode.

The purpose of this study is to evaluate whether pressure support settings suggested by the B3 system and pressure support as well as Positive End Expiratory Pressure (PEEP) settings suggested by the B5 system, i.e. balancing under and over support based upon physiological models and simple clinical measures, are consistent with keeping patients within appropriate levels of support as assessed by the ratio between airwaiy pressure generated by the respiratory muscles (Pmus) and the maximum inspiratory pressure (MIP) (Pmus/MIP), the ratio between the inspiratory time (TI) and total respiratory time (TTOT) (TI/TTOT) and the Tension-Time index (TTi), these being obtained using less frequently used esophageal catheter measurements.

Eligibility Criteria:
Inclusion Criteria:

* Under mechanical ventilation in Pressure Support mode

Exclusion Criteria:

* Neuromuscular impairment
Socket Preservation Using Socket-plug Technique With Alloplastic Putty Bone Versus Ice Cream Cone Technique in Extraction Socket With Buccal Dehiscence.

Socket Preservation Using Socket-plug Technique with Alloplastic Putty Bone Versus Ice Cream Cone Technique in Extraction Socket with Buccal Dehiscence: A Randomized Controlled Clinical Trial.

this randomized controlled clinical trial evaluates the effect of using alloplastic putty bone with socket-plug technique versus ice-cream cone technique regarding dimensional changes in bone width

Eligibility Criteria:
Inclusion Criteria:

* Single or double rooted teeth indicated for extraction.
* Systemically free patient
* Presence of small buccal dehiscence not exceeding 1/3 of the root.
* Maxillary and Mandibular Arches
* Non-smoker
* Adults or above the age of 21.
* Able to tolerate surgical periodontal procedures.
* Full mouth plaque and bleeding scores less than 15%.
* Compliance with the maintenance program.
* Provide informed consent

Exclusion Criteria:

* Systemic conditions/disease that contraindicate surgical procedure.
* Patients with presence or history of osteonecrosis of the jaws, with use of bisphosphonates, exposure to head and neck radiation, chemotherapy.
* Extraction socket with intact walls with no buccal dehiscence
* Patients with large distinct pre-apical pathology
* Heavy Smokers more than 10 cigarettes a day
* Patients without availability to attend follow-up visits or patients rejecting to sign the informed consent.
* Patients with parafunctional habits that produce overload on implant, such as bruxism and clenching.
Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

To determine what side effects and what clinical effect, if any, the administration of this investigational product, IDEC-114 in combination with Rituxan® \[Rituxan® as a single agent is approved by the United States Food and Drug Administration (FDA) to treat patients with relapsed or refractory follicular NHL\], has in this patient population.


Eligibility Criteria:
Inclusion Criteria:

* Signed IRB-approved informed consent
* Greater than or equal to 18 years of age
* Proof of follicular lymphoma
* Progressive disease requiring treatment after at least 1 prior standard therapy
* Acceptable hematologic status, liver function, and renal function
* Patients of reproductive potential must agree to follow accepted birth control methods during treatment and for 3 months after completion of treatment

Exclusion Criteria:

* No response to prior Rituxan® or Rituxan®-containing regimen
* Presence of CLL or CNS lymphoma
* Known history of HIV infection or AIDS
* Prior diagnosis of aggressive NHL or mantle-cell lymphoma
* Serious nonmalignant disease
* Pregnant or currently breast feeding
Characterization of Adult Subjects for Asthmatic Research Studies

This study is designed to characterize subjects in terms of the nature and severity of their asthma and in terms of conditions that may alter the clinical expression of asthma. Some features will be obtained in all subjects. These include a medical history and baseline lung function tests. This characterization forms the basis for our database that facilitates research protocols.

The purpose of this study is to generate a cohort of well-characterized asthmatic subjects as a resource for recruitment of asthmatic subjects and healthy controls in clinical studies and clinical trials in the UCSF Airway Clinical Research Center. The UCSF Airway Clinical Research Center (ACRC) conducts multiple clinical research studies in asthma funded by the NIH, foundations, and industry. We have a broad range of research interests, but we have specific interests in mechanism-oriented clinical studies and specific expertise in biospecimen collection, biobanking, and biospecimen analysis. Our model is to have multiple studies recruiting simultaneously, and this means that we need well-organized recruitment and database systems.

Additionally, we aim to characterize asthmatic subjects in multiple domains, including disease severity, airway inflammation subtypes, and mucus subtypes. Asthma is a heterogeneous disease in its clinical presentation and in its underlying cellular and molecular phenotypes. To explore cellular and molecular phenotypes of asthma, we will analyze induced sputum for cell types and gene expression, with a focus on Th2 inflammation pathways and innate and adaptive immune cells that drive Th2 inflammation. Detailed cellular analysis of sputum is possible but requires that multiple sputum samples be collected for processing in multiple different ways, including by cytocentrifugation, FACS analysis, and by formalin fixation and paraffin embedding of sputum cell pellets. We are also studying mucus phenotypes of asthma using methods of rheology, which needs to be done on fresh sputum.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 years and older

Exclusion Criteria:

* History of lung disease other than asthma
* An upper respiratory tract infection or an exacerbation of their asthma within the preceding 4-6 weeks.
* Persons who have smoked \> 5 cigarettes per month and have a total pack-year smoking history \> 10 packs.
Transcultural Multidisciplinary Evaluation of Patients With Hemophili

Multidisciplinary evaluation of patients with hemophilia Spain, El Salvador and Bolivia. It aims to analyze and evaluate the skeletal muscle of patients affected with hemophilia Spain, El Salvador and Bolivia; describe deficit mobility and muscular strength, depending on the degree of injury, age, presence of inhibitors and the development of physical activity; identify the relationship between the functional deficit by clinical assessment performed with the use of validated measurement scales, the assessment of the degree of injury to specific scales of hemophilia; detect biomechanical alterations of the lower limbs and their impact on gait in patients with hemophilia; and evaluate the factors that influence the perception of illness and quality of life of patients with hemophilia.

Descriptive study of joint involvement in patients with hemophilia Spain, El Salvador and Bolivia.

Descriptive study of abnormal joint mobility and muscle strength as a result of acute conditions or the development of chronic articular sequelae.

Descriptive study of biomechanical changes in lower limb joints and their impact on gait in patients with hemophilia.

Descriptive study of the overall articular involvement (crepitus, pain, biomechanical and functional changes) in patients with hemophilia.

Descriptive study of the relationship between skeletal muscle pathology in patients with hemophilia and their perception of it, and their quality of life.

Eligibility Criteria:
Inclusion Criteria:

* Patients with hemophilia A and B.
* Patients of all ages (pediatric, adolescents, youth and adults).
* With or without joint involvement clinically diagnosed, and with or without a previous history of hemarthrosis joint load legs.
* Patients with or without inhibitors.

Exclusion Criteria:

* Patients without prior ambulation capacity.
* Patients diagnosed with other congenital coagulopathy (von Willebrand disease, etc..).
* Patients with neurological or cognitive impairments that prevent understanding the questionnaires and physical tests.
Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B

This study evaluates the addition of glycyrrhizin to entecavir in the treatment of patients with chronic hepatitis B in China. Half of participants will receive magnesium isoglycyrrhizinate followed by oral diammonium glycyrrhizinate and entecavir in combination, while the other half will receive a placebo and entecavir.

Chronic hepatitis B(HBV) has a high prevalence (\>8%) in China. Entecavir, aguanosine analog, is a potent and selective inhibitor of HBV DNA polymerase.

Glycyrrhizin has been used for more than 30 years in the treatment of liver diseases in Asian countries, who can relieve necro-inflammatory and liver fibrosis or cirrhosis Recent study has shown that inflammation plays the important role in chronic HBV and fibrosis or cirrhosis disease progression, but antiviral therapy only may not reduce inflammation ideally. The addition of glycyrrhizin to entecavir in the treatment may slow disease progression in patients with chronic HBV and advanced fibrosis or cirrhosis.

Eligibility Criteria:
Inclusion Criteria:

* Hepatitis B surface antigen \[HBsAg\]-positive,
* Either hepatitis B e antigen (HBeAg)-positive or HBeAgnegative/hepatitis B e antibody (HBeAb)-positive disease were eligible,
* Serum alanine aminotransferase (ALT) levels 3-10×the upper limit of normal (ULN),serum total bilirubin(TBIL)levels\<2×ULN

Exclusion Criteria:

* Co-infection with hepatitis C virus, hepatitis D virus, or human immunodeficiency virus;
* Other forms of liver disease;
* More than 24 weeks of therapy with a nucleoside or nucleotide analog with activity against HBV, and therapy with any anti-HBV drug within 24 weeks prior to randomization;
* More than 12 weeks of therapy with liver protectants, and therapy with glycyrrhizin;
* Has decompensated liver function or has a hint of hepatocellular carcinoma (HCC);
* During the study patients were not allowed to use other medicines.
Improve Management of Heart Failure With Procalcitonin

Patients presenting to the Emergency Department with shortness of breath and (suspected) heart failure will be screened and randomized to either a standard of care or a procalcitonin-guided arm.

Procalcitonin-guided arm: a procalcitonin level (cutoff 0.2 ng/ml) will be used to support decision on antibiotic therapy initiation.

Standard of care arm: the decision on antibiotic therapy will be based on the physicians intent to treat.

The patients will be followed up 30 and 90 days after randomization to evaluate the survival status, re-hospitalizations and further antibiotic therapies.


Eligibility Criteria:
Inclusion Criteria:

1. Patients who present to the emergency department (ED) with leading symptom dyspnea
2. Suspected or known heart failure
3. midregional pro atrial natriuretic peptide (MR-proANP)\>300 pmol/L, brain natriuretic peptid (BNP) \>350 ng/ml or N-terminal of the prohormone brain natriuretic peptide (NT-proBNP)\>1800 ng/l
4. Patient has given written Informed Consent within study timelines to allow antibiotic therapy within 8 hours
5. Adult patients (i.e. \>18 years of age)
6. Hospitalization for at least 1 overnight stay planned

Exclusion Criteria:

1. Patient participates in any other interventional clinical trial
2. Trauma related shortness of breath
3. Patient diagnosed with lung or thyroid cancer
4. Known terminal disease with life expectancy of less than 6 months, e.g. advanced metastasized cancer disease
5. Organ transplant requiring immunosuppression
6. Abdominal, vascular or thorax surgery within the last 30 days
7. End stage/advanced heart failure - defined by planned heart transplantation, or cardiogenic shock
8. Female patients who have given birth within 3 months before study enrolment
9. Current use of antibiotics or requirement of immediate antibiotic therapy before randomization and measurement of Procalcitonin
10. End stage renal failure requiring dialysis
11. Patient is not willing, or it is not possible or advisable for the patient, to follow the study schedule, including antibiotic therapy and 90 days follow up
12. Patient has already participated in the clinical trial previously
13. Pregnant or lactating women
14. Patients who are institutionalized by official or judicial order
15. Dependants of the sponsor, the contract research organization (CRO), the study site or the investigator
Effective Methods of Reducing Lower Back, Neck and Shoulder Pain Among Office Workers

Background:Musculoskeletal discomforts (MSD), especially in the neck, lower back and shoulder areas, are some of the most common issues among office workers. The Social Security Organization (SOCSO) in Malaysia caps number of cases involving musculoskeletal injuries at a maximum of 10,000 per year.

Objectives: The primary aims of this research were to: 1. Measure the prevalence of MSD in a sample of office workers; 2. Test effective methods of reducing lower back, neck and shoulder pain in this sample by training exercise, or ergonomics modification, or both of them; and 3. Assess discomfort scores and the range of motion of the lower back, neck and shoulder muscles among the office workers after undertaking the different methods for a period of 6 months.

Methods: In a true experimental design, from 10,000 staff in Telecom Malaysia,onehundred and forty two office workers (of whom 50 were male), aged 20-50 y, were allocated randomly, from 3 different locations (Bangsar, Puchung, and Damansara), to one of three intervention groups (receiving training exercise, receiving modified ergonomics, receiving a combination of exercise and ergonomics modification) and a control group (receiving none of these interventions). The Cornell MSD Questionnaire was used to measure musculoskeletal discomforts, with focus on pain severity, before treatment and after 2, 4 and 6 months of the interventions. The range of motion (ROM) of the hip, neck, shoulder and knee were measured by a 12 inch goniometer, and the Borg CR10 scale was used to measure the perceived exertion of training exercises. The rapid office strain assessment (ROSA) questionnaire was used to assess the strain associated with office work. Height and weight were also measured to calculate the body mass index (BMI).

It is expected that, 6 months intervention including exercise training, ergonomic modification and mixture of these 2 intervention, maybe can decrease the severity of pain in lower back, neck and shoulder among office workers.

Eligibility Criteria:
Inclusion Criteria:

* Working in office

Exclusion Criteria:

* Any physical or mental disease any surgery in background any limitation by Dr
Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection

OBJECTIVES:

I. Evaluate the efficacy of ganciclovir (12 mg/kg per day) versus no treatment in neonates with symptomatic congenital cytomegalovirus infection with central nervous system disease.

PROTOCOL OUTLINE: This is a randomized study. Patients are stratified by participating institution.

Patients are randomly assigned to no antiviral therapy or intravenous ganciclovir every 12 hours for 6 weeks.

Patients are followed at weeks 1-4 and 12, months 6, 12, 24, 36, 48, and 60, and yearly thereafter until puberty (when possible).

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

* Symptomatic cytomegalovirus (CMV) infection: Central nervous system disease, with or without other organ system involvement, e.g.: Microcephaly, i.e., less than 5% for age Radiologic changes indicating brain disease Cerebrospinal fluid exam abnormal for age Chorioretinitis Hearing defects
* CMV confirmed by urine, throat, buffy coat, and/or conjunctiva culture
* No hydroencephalopathy or other devastating brain involvement

--Prior/Concurrent Therapy--

* No concurrent antiviral agent No concurrent immune globulin

--Patient Characteristics--

* Age: Under 1 month (preferably under 2 weeks)
* Life expectancy: No imminent demise
* Renal: Creatinine no greater than 1.5 mg/dL
* Other: Birth weight at least 1200 g Gestational age at least 32 weeks No HIV infection No concurrent bacterial infection Eligible if resolved following 2-week treatment and CMV symptoms persist